Actinium Pharmaceuticals announced new data presentations for its ATNM-400 targeted radiotherapy at the SNMMI 2026 Annual Meeting, highlighting its potential in prostate and non-small cell lung cancers. The company also disclosed a notice from NYSE American about non-compliance with listing standards due to low stockholders' equity and ongoing losses, requiring a compliance plan by June 26, 2026. Despite this, Actinium plans to continue trading and aims to regain compliance by November 2027. Upcoming catalysts for its pipeline therapies are expected in the second half of 2026, signaling ongoing development progress.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
